Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 132, Issue , 2017, Pages 157-168

  Molugulu, Nagashekhara ^a   Yee, Lai Shu ^a   Ye, Yew Tze ^a   Khee, Tan Chew ^a   Nie, Lee Zhen ^a   Yee, Neoh Jia ^a   Yee, Tian Kar ^a   Liang, Tan Chee ^a   Kesharwani, Prashant ^b  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Canagliflozin; Dapagliflozin; Empagliflozin; HbA1c; Metformin; SGLT2 inhibitors; Type 2 diabetes mellitus

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; HEMOGLOBIN A1C; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

COMBINATION DRUG THERAPY; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; GLYCEMIC CONTROL; HUMAN; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT REDUCTION; ADOLESCENT; ADULT; AGED; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; MALE; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; YOUNG ADULT;

EID: 85027194727     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2017.07.025     Document Type: Review

References (15)

1. Diabetes mellitus (Internet). WHO. (cited 2017 Mar 1). Available from: < http://www.who.int/mediacentre/factsheets/fs138/en/>.
2. Non-communicable disease, risk factors and other health problems. National health and morbidity survey 2015. Ministry of Health Malaysia 2015;2:14–6.
3. Mortality among type 2 diabetic in-patient in a nigerian tertiary hospital. AJDM. November 2016;24(2):14–20.
4. Inzucchi, S.E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 12:2 (2015 Mar), 90–100.
5. Tan, X., Hu, J., Combination therapy for type 2 diabetes: dapagliflozin plus metformin. Expert Opin Pharmacother 17:1 (2016), 117–126.
6. Bailey, C.J., Morales Villegas, E.C., Woo, V., Tang, W., Ptaszynska, A., List, J.F., Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabet Med J Br Diabet Assoc 32:4 (2015 Apr), 531–541.
7. Cuypers, J., Mathieu, C., Benhalima, K., Sglt2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of Sglt2-Inhibitors in clinical practice. Acta Clin Belg 68:4 (2013 Aug 1), 287–293.
8. Schumm-Draeger, P.-M., Burgess, L., Korányi, L., Hruba, V., Hamer-Maansson, J.E., de Bruin, T.W.A., Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial. Diabetes Obes Metab 17:1 (2015 Jan), 42–51.
9. Rosenstock, J., Aggarwal, N., Polidori, D., Zhao, Y., Arbit, D., Usiskin, K., et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35:6 (2012 Jun), 1232–1238.
10. Rosenstock, J., Seman, L.J., Jelaska, A., Hantel, S., Pinnetti, S., Hach, T., et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 15:12 (2013 Dec), 1154–1160.
11. Bolinder, J., Ljunggren, Ö., Johansson, L., Wilding, J., Langkilde, A.M., Sjöström, C.D., et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16:2 (2014 Feb), 159–169.
12. Merker, L., Häring, H.-U., Christiansen, A.V., Roux, F., Salsali, A., Kim, G., et al. Empagliflozin as add-on to metformin in people with type 2 diabetes. Diabet Med J Br Diabet Assoc 32:12 (2015 Dec), 1555–1567.
13. Rosenstock, J., Chuck, L., González-Ortiz, M., Merton, K., Craig, J., Capuano, G., et al. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naïve type 2 diabetes. Diabetes Care 39:3 (2016 Mar), 353–362.
14. Zou, Honghong., Zhou, Baoqin., Gaosi Xu SGLT2 inhibitors:a novel choice for the combination therapy in diabetic kidney disease. Cardiovasc Diabetrol, 16, 2017, 65.
15. Elisaf, M., Tzavela, E., Karanatsis, N., Tsimichodimos, V., Antidiabetic drugs and the kidney. Curr Pharm Des, 2017, 10.2174/138161282366617030710 3222.